224 related articles for article (PubMed ID: 39306)
1. The dopamine hypothesis of schizophrenia revisited.
van Kammen DP
Psychoneuroendocrinology; 1979 Jan; 4(1):37-46. PubMed ID: 39306
[No Abstract] [Full Text] [Related]
2. Intrinsic mesocorticolimbic connectivity is negatively associated with social amotivation in people with schizophrenia.
Xu P; Klaasen NG; Opmeer EM; Pijnenborg GHM; van Tol MJ; Liemburg EJ; Aleman A
Schizophr Res; 2019 Jun; 208():353-359. PubMed ID: 30711314
[TBL] [Abstract][Full Text] [Related]
3. Mesolimbic system and tardive dyskinesia: new perspectives for therapy.
Cools AR
Mod Probl Pharmacopsychiatry; 1983; 21():111-23. PubMed ID: 6140628
[No Abstract] [Full Text] [Related]
4. Schizophrenia: D4 receptor elevation. What does it mean?
Seeman MV
J Psychiatry Neurosci; 1994 May; 19(3):171-6. PubMed ID: 7913338
[No Abstract] [Full Text] [Related]
5. Reevaluation of the mesolimbic hypothesis of antipsychotic drug action.
Lidsky TI
Schizophr Bull; 1995; 21(1):67-74. PubMed ID: 7770742
[TBL] [Abstract][Full Text] [Related]
6. The role of limbic and cortical regions in schizophrenia: focus on dopamine.
Marchese G; Pani L
Eur Psychiatry; 2002 Aug; 17 Suppl 4():349s-354s. PubMed ID: 23573604
[TBL] [Abstract][Full Text] [Related]
7. [Possible participation of limbic structures of the forebrain in the mechanism of the antipsychotic effect of neuroleptic preparations in schizophrenia (review)].
Aksent'ev SB; Mokhovikov AN
Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(8):1254-60. PubMed ID: 6137921
[No Abstract] [Full Text] [Related]
8. Phenomenological modelling of some mechanisms in schizophrenia.
Schwegler H
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S43-9. PubMed ID: 16508895
[TBL] [Abstract][Full Text] [Related]
9. New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia.
Scheel-Krüger J; Arnt J
Psychopharmacology Suppl; 1985; 2():46-57. PubMed ID: 2987907
[TBL] [Abstract][Full Text] [Related]
10. Dopamine, the prefrontal cortex and schizophrenia.
Knable MB; Weinberger DR
J Psychopharmacol; 1997; 11(2):123-31. PubMed ID: 9208376
[TBL] [Abstract][Full Text] [Related]
11. Biochemical aspects of Parkinson's disease.
Nagatsu T
Adv Neurol; 1993; 60():165-74. PubMed ID: 8093575
[No Abstract] [Full Text] [Related]
12. Basal ganglia and Parkinson's disease: neurobiological and pharmacological aspects in animals and man.
Cools AR
Clin Neurol Neurosurg; 1984; 86(3):178-95. PubMed ID: 6091966
[TBL] [Abstract][Full Text] [Related]
13. Schizophrenia: a subcortical neurotransmitter imbalance syndrome?
Carlsson M; Carlsson A
Schizophr Bull; 1990; 16(3):425-32. PubMed ID: 1981107
[TBL] [Abstract][Full Text] [Related]
14. The neuropathology of schizophrenia.
Bachus SE; Kleinman JE
J Clin Psychiatry; 1996; 57 Suppl 11():72-83. PubMed ID: 8941174
[TBL] [Abstract][Full Text] [Related]
15. An anatomy of schizophrenia?
Stevens JR
Arch Gen Psychiatry; 1973 Aug; 29(2):177-89. PubMed ID: 4147475
[No Abstract] [Full Text] [Related]
16. [Biochemistry of schizophrenia and mechanism of action of neuroleptics].
Loo H; Cuche H; Sechter D
Sem Hop; 1982 Dec; 58(44):2565-72. PubMed ID: 6130604
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
[TBL] [Abstract][Full Text] [Related]
18. Dopamine and schizophrenia: an analysis of the theory.
Carlton PL; Manowitz P
Neurosci Biobehav Rev; 1984; 8(1):137-51. PubMed ID: 6145134
[TBL] [Abstract][Full Text] [Related]
19. [Neuroendocrinology and schizophrenia research].
Müller-Spahn F
Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
[No Abstract] [Full Text] [Related]
20. Gaba blockade, dopamine and schizophrenia: experimental activation of the mesolimbic system.
Stevens JR
Int J Neurol; 1975; 10(1-4):115-27. PubMed ID: 1237474
[No Abstract] [Full Text] [Related]
[Next] [New Search]
